Dr Ranjana Srivastava - Biotechresearch

chatteryellvilleΒιοτεχνολογία

20 Φεβ 2013 (πριν από 4 χρόνια και 4 μήνες)

355 εμφανίσεις

Ranjana Srivastava

+91
-
9335
-
819
-
609

ranjana@biotechresearch.in


Former
Head


Microbiology Division

Central Drug Research Institute
, Lucknow


An astute professional w
ith

38

years of rich &

qualitative experience in
scientific domain. A
blend
of
successful science

&
people management


which includes building the vision of the department, people

management & future projection, appraisal
s of

development of people within team and department
.
Over the years, have participated in national & international committees, meetings & conferences,
publications in journals; with an aspiration to contribute to the overall scientific development and growth.


Core Strengths

* Microbiology





*
Biotechnolog
y

* Molecular Biology







Professional Background




Scientist G (till 2011)

with Central Drug Research Institute, India




Post Doctorate

Res
earch Associate with Brown University, Providence, USA from
1978
-
82




University of Brussels, Belgium

from
1972
-
74


Deputation abroad




DBT Overseas Research Associate
-
ship with
Center for Vaccine Development
, Baltimore, USA


In 1988






Visiting Scientist
(Indo


US VAP) with

Center for Vaccine Development
, Baltimore, USA in


1990, 1991, 1992 & 1993





Visiting
Scientist

(Indo


French) with
Institute Pasteur de Lille
, Lille, France in 2002 & 2004





Areas of research





Genetics of
E. coli

RNA Polymerase



Pathogenesis of
Vibrio cholerae



Molecular basis for band and interband pattern in polytene

chromosomes of fungus fly
Sciara
coprophila



Cellulose degradation



Tuberculosis


Significant Milestones


Development of a DNA diagnostic probe for Tuberculosis


By molecular cloning and DNA hybridization, a repetitive sequence specific to
Mycobacterium

tuberculosis

was selected which was developed as diagnostic probe to detect tubercle bacilli in clinical
fluids. The probe was sequenced to establish the novelty, uniqueness and specificity was established with
thousands of clinical isolates of
M.
tuberculosis

and clinical specimens

and

patent in India, Europe and
USA was obtained. PCR based diagnostic assay detects
M.tuberculosis

DNA which has been brought to
Real Time PCR platform with Taqman technology. It has been commercialized as “MycoVi
ew MTB PCR
detection kit” by Central Drug Research Institute (CDRI).


Development of surrogate screens for high throughput screening of anti
-
TB compounds


User friendly nonhazardous rapid screens have been developed to preselect active anti
-
TB compounds

using
apathogenic, non hazardous
M. bovis

BCG and
M. aurum

as surrogate strains and GFP and firefly
luciferase as reporters.
Use of these reporter strains allow to select an active compound

within 48 h

which were further

validated in isolation on recom
binant
M.tuberculosis

expressing GFP or luciferase.

M. aurum

as surrogate strain of
M
.
tuberculosis
for screening FasII inhibitors


developed using protein
-
protein interaction and bacterial two hybrid system.


Mining new drug targets from TB genome by
genetic approaches


Branched chain amino acids (BCAA; isoleucine, leucine and valine; ILV) biosynthesis pathway was explored
for novel targets for the development of new anti TB drugs as BCAA auxotrophs of mycobacteria fail to
grow in the host.

Another a
pproach used
in vivo

expression technology (IVET)

and
in vivo

induced
antigen technology (IVIAT) for selection of genes expressed during infection of
M. tuberculosis

in
macrophages, mice and human.
A novel vector was developed with a bicistronic reporter

for cloning of
functional promoters during infection in macrophages and in mice.
The bicistronic reporter is a
transcriptional fusion of promoterless green fluorescent protein and kanamycin resistance genes.

The
selection strategy lies in selection of fluorescent kanamycin resistant clones surviving in the
macrophages/
lungs after giving kanamycin assault to
macrophage/
mice. One of the gene identified by IVIAT, Rv3303c
has been characterized as virulence fac
tor which protects TB bacilli against oxidative stress and is
upregulated during infection
ex vivo

and
in vivo
.



New chemical entities


A number of synthetic lead anti
-
TB compounds
were

identified which are classified as (i) glycosylated
propanamides

(b) glycosylated and substituted ureas and thioureas (c) diglycoxylated diaminoalcohol (d)
substituted amino glycosidated popanoates (e) phenyl cyclopropyl methanomes (f) thiazidine thiones (g)
galactopyranosylated amino alcohols (h) daryloxy methane phe
nanthrenes (i) ICL /arylalkyl dideoxy
glucopyranisides . IPR
has been secured and published
.


Development of
in vivo

murine infection model for
M. fortuitum


A murine infection model for
M. fortuitum

was developed which displays active and chronic infection. The
infection produce characteristic visible disease symptoms which disappeared during chronic infection.
Administration of drug resulted in loss of symptoms in infected mice thus making it a rapi
d
in

vivo

screening model

and was used to screen compounds active against NTM infection.




Scholastics

& Awards



Ph.D. students guided


17

MD Thesis



6


Awards


Shakuntala Amirchand Prize of ICMR


1986

CSIR New Idea Fund




2005




Publications


1.

R.
Srivastava
, C. Toussaint and J.P. Lecocq
1974
.
A rifampicin resistant mutation of E. coli whose
phenotypic expression is dependent on the composition of the medium and recA allele.
Mutation
Res.

23, 25.

2.

R. Srivastava
, V.B. Sinha, B.S. Srivastava.
1979.

Re
-
evaluation of antibacterial and anti
-
toxin
immunities in experimental cholera
. Ind. J. Med. Res
.
70, 369.

3.

B.S. Srivastava, V.B. Sinha,
R. Srivastava
.
1979.

Attenuated recombinant strains of
Vibrio cholerae

for
oral immunization.
Bull. Wld. Hlth.
Org
.
57, 649.

4.

R. Srivastava
, V.B. Sinha, B.S. Srivastava.
1980
. Events in the pathogenesis of experimental cholera:
role of bacterial adherence and multiplication
.
J. Med.

Microbiol
.
13, 1.

5.

R. Srivastava
, B.S. Srivastava.
1980
. Isolation of a non
-
adhesiv
e mutant of
Vibrio cholerae

and
chromosomal localization of the gene controlling mannose sensitive adherence to intestinal mucosa
.
J. Gen. Microbiol
.
117, 275.

6.

A.A. Khan,
R. Srivastava
, V.B. Sinha, B.S. Srivastava
. 1985. Regulation of toxin biosynthesis by plasmids
in
vibrio cholerae
.
J. Gen. Microbiol
.
131, 2653.

7.

R. Srivastava
, A.A. Khan, B.S. Srivastava.
1985.

Immunological detection of cloned antigenic genes of
Vibrio cholerae

in
Escherichia coli
.
Gene
, 40,
267.

8.

R. Srivastava
, V.B. Sinha, B.S. Srivastava
1989

.
Chromosomal; transfer and in vivo cloning of genes in
Vibrio cholerae using RP4::mini
-
Mu.
Gene
75, 253.

9.

A.W. Kerrebroeck,
R. Srivastava
, S.A. Gerbi.
1989. Isolation and characterization of ribosomal
DNA
variants from
Sciara coprophila
.
J. Mol. Biol
.
210, 1.

10.


J.R. Czezulin,
R. Srivastava
, B.S. Srivastava, J.B. Kaper. 1990. Characterization of a possible colonizing
factor of
Vibrio cholerae
. 01.
Proc. Amer. Soc. Microbiol
. 108.

11.

R. Srivastava
, R. Bharti, A.K. Srivastava.
1990
. Characterization of a novel cellobiase from
Bacillus
subtilis

and expression of its structural gene in
Escherichia coli
.
Biotech. Lett
.
12, 541.

12.

R. Srivastava
, S. S. Ali, B. S. Srivastava.
1991
. Cloning of xylanase gene
of
Streptomyces flavogriseus

in
Escherichia coli

and bacteriophage lambda induced lysis for the release of cloned enzyme.
FEMS
Microbiol Lett
.
78, 201.

13.

C.K.M. Tripathi, S.S. Ali,
R. Srivastava
.
1992
. Characterization of xylanase activity of
Streptomyces
wedmorensis
.
Ind. J. Exptl. Biol
. 30, 741.

14.

A. Jacob,
R. Srivastava
, V.B. Sinha, M.K. Sahib, J.B. Kaper, B.S. Srivastava.
1993
.

Identification of a 33
kDa antigen associated with an adhesive and colonizing strain of
Vibrio cholerae

el tor and its role in
protection.
Vaccine,

11, 376.


15.

V.B. Sinha, A. Jacob,
R. Srivastava

,J.B. Kaper, B.S. Srivastava.
1993
.

Identification of the flagellar
antigens of

Vibrio cholerae

el tor and their role

in protection.
Vaccine
,

11, 372
A.

16.

R.
Srivastava
, A.K. Srivastava.
1993
. Characteriozation of a bacterial xylanase resistant to repression
by glucose and xylose.
Biotech. Lett.

15, 847.

17.


K.

Krishna Kumar,
R, Srivastava
, V.B. Sinha, J. Mechalski, J.B. Kaper, B.S.Srivastava.
1994
.
rec
A

mutations reduce adherence and colonization of classical and el tor strains of
Vibrio cholerae
.
Microbiology

140
, 1217.

18.

S.N. Singh,
R. Srivastava
, V.B. Sinha, B.S. Srivastava.
1994
. A 53 kDa protein of
Vibrio cholerae

classical
strain 0395 involved in in
testinal colonization.
Microbial Pathogenesis

17, 69.


19.


R. Srivastava
, G. Prasanna Kumar, K.K. Srivastava.
1995
. Genetic construction of a cellulolytic
Escherichia coli
.
Gene

164, 185.

20.

D. Kumar, B.S. Srivastava, N. B. Singh,
R.
Srivastava
.
1996
. Identification of a 25 kDa protein of
Mycobacterium bovis

BCG to distinguish BCG from
Mycobacterium tuberculosis
.

J. Clin. Microbiol
.

34,
224.


21.

R. Srivastava
, D. Kumar, P Subramaniam, B.S. Srivastava.
1997
.

-

galactosidase reporter system in
mycobac
teria and its application in rapid

antimycobacterial drug screening.
Biochem. Biophys. Res.
Commun.

235
,


602.


22.

R.

Srivastava
, D. Kumar, B. S. Srivastava.
1997.

Recombinant
Mycobacterium

aurum

expressing

Escherichia coli


-
galactosidase

in high through put

screening of antituberculosis drugs.
Biochem.
Biophys. Res. Commun
.
240, 536.

23.

V.P.


Bondre,
R. Srivastava
, V.B. Sinha, B.S. Srivastava.
1997
. Screening of Tn
pho
A mutants of
Vibrio
cholerae
0139 for identification of antigens involved
in colonization
.
J. Med. Microbiol
. 46, 1007.

24.

A.Shukla, M.P. Dubey,
R.Srivastava
, B.S. Srivastava .
1998.

Differential expression of proteins during
healing of cutaneous wounds in experimental and normal and chronic models.
Biochem. Biophys. Res.
Commun
.
24
4, 434.

25.

D. Kumar, B.S. Srivastava,
R. Srivastava
.
1998
. Genetic rearrange
-
ments leading to disruption of
heterologous gene expression in mycobacteria: An observation with

-
galactosidase in
Mycobacterium smegmatis
.
Vaccine,

16,


1212.

26.

R. Srivastava
, D.K. Deb, K.K. Srivastava, C. Locht, B. S. Srivastava.
1998
. Green fluorescent protein as a
reporter in rapid screening of antituberculosis compounds
in vitro

and in macrophages.
Biochem.
Biophys. Res. Commun.
.
253, 431.

27.

R.

Srivastava
, B.S. Srivastava.

2000.

Tuberculosis vaccines.
IDrugs
,
3,

408.

28.

D.K.Deb, K.K.Srivastava,
R. Srivastava
, B.S. Srivastava.
2000
. Bioluminescent
Mycobacterium aurum

expressing firefly luciferase for

rapid and high throughput screening of antimycobacterial drugs
in
vitro


and in infected macrophages.
Biochem. Biophys. Res. Comm
.
279,

457.


29.

R. Srivastava
, B.S.Srivastava.
2000.

Tuberculosis vaccines: a critical role for T
-
cells.
Curr. Opinion

Anti
-
inflammatory & Immunomodu
latory

Investigational Drugs

2 (2), 100.

30.

M. Waskar, D. Kumar, A. Kumar,
R. Srivastava
.
2000
. Ioslation of a novel insertion sequence from
Mycobacterium fortuitum

using a trap vector based on inactivation of a lacZ reporter gene.
Microbiology
,
146, 1157.

31.

R.Prasad, S.K. Lath, P.K., Mukerji, S.K., A
garwal,
R.

Srivastava,.
2001.

Clinical utility of Polymerase
chain reaction in patients of Pulmonary Tuberculosis.
Ind. J. Tub
. 48, 135.

32.

R. Pathak, C. S. Pant, A. K. Shaw, A. P. Bhaduri, A. N. Gaikwad, S. Sinha, A. Srivastava, K. K. Srivastava,
V.
Chaturvedi,
R. Srivastava,

B. S. Srivastava
. 2002.

Baylis
-
Hillman Reaction: Convenient ascending
syntheses and biological evaluation of Acyclic Deoxy monosaccharides as potential antimycobacterial
agents
. Biorg. Med. Chem
. 10,

3187.


33.

R. Pathak, A. K. Sh
aw, A. P. Bhaduri, K. V. G. Chandrasekhar, A. Srivastava, K. K. Srivastava, V.
Chaturvedi,
R. Srivastava
, B. S. Srivastava, S. Arora, S. Sinha.
2002
. Higher acyclic nitrogen containing
deoxy sugar derivatives: a new lead in the generation of antimycobacter
ial chemotherapeutics
.
Biorg.
Med. Chem.

10
, 1695.

34.

R.P.

Tripathi, R. Tripathi, V.K. Tiwari, L. Bala, S.
Sinha, S.A. Srivastava,
R.

Srivastava,

B.S. Sivastava.
2002.

Synthesis of glycosylated B
-
amino acids as new class of antitubercular agents.
Eur. J. M
ed.
Chem.

37
,
773.


35.

D.K. Deb, P. Dahiya, K.K. Srivastava,
R. Srivastava
. B.S. Srivastava.
2002
. Selective identification of
new therapeutic targets of
Mycobacterium tuberculosis

by IVIAT approach
. Tuberculosis 82
, 175.

36.

D. Katiyar, V.K. Tiwari, R.P.
Tripathi, A. Srivastava, V. Chaturvedi,
R.

Srivastava
., B.S. Srivastava.
2003
.
Synthesis an antimycobacterial activity of 3,5
-
disubstituted thiadiazine thiones.
Bioorg. Med. Chem
.
11, 4369.

37.

A.Mishra, A.,
R. Srivastava
, C. Pruzzo, B.S. Srivastava.
2003
. Mu
tation in
tcp
R gene (Vc0832) of
Vibrio
cholerae

O1 causes loss of tolerance to high osmolarity and affects colonization and virulence in infant
mice.
J. Med. Microbi
ol.
52, 1.

38.

P. Prem Raj, S. Srivastava, S. K. Jain, B. S. Srivastava,
R.
Srivastava
..
200
3
. Protection by live
Mycobacterium habana

cvaccine against
Mycobacterium

tuberculosis

H37Rv challenge in mice.
Indian
J. Med. Res
.
117, 139.

39.

G. Panda, Shagufta , J. K. Mishra, V. Chaturvedi, A. K. Srivastava, R. Srivastava, B.S. Srivastava
2004
.
Diarylo
xy methano phenanthrenes: a new class of antituberculosis agents.
Bioorg. Med. Chem
.

12 .
5269.

40.

D. Katiyar, V.K. Tiwari, N. Tiwari, S.S. Verma, S. Sinha, A. Gaikwad, A. Srivastava, V., Chaturvedi, R.
Srivastava, B.S. Srivastava and R.P. Tripathi
.
2005
. Sy
nthesis of antimycobacterial activity of Glosylated
Aminesand Amino Alcohols..
Eur. J. Med. Chem
.40,(2005) 351.

41.

M. Zampini, C. Pruzzo, V.P. Bondre, R. Tarsi, M. Cosmo, A. Bacciaglia, A. Chabbra, R. Srivastava, B.S.
Srivastava..
2005
.
Vibrio cholerae

persistence in aquatic environments and colonization of intestinal
cells: involvement of a common adhesion mechanism.
FEMS Microbiol. Lett
. 244 , 267.

42.

R.P.S. Parti, S. Srivastava, R. Gachhui, K.K. Srivastava,
R. Srivastava.

2005.

Murine infection model f
or
Mycobacterium fortuitum
.
Microbes and Infection
. 7, 349.

43.

R. Srivastava
, D. Kumar, M.N. Waskar, M. Sharma, V.M. Katoch, B.S. Srivastava.
2006
. Identification of
a repetitive sequence belonging to a PPE gene of
Mycobacterium tuberculosis

and its use in di
agnosis
of tuberculosis
.
J. Med. Microbiol
. 55, 1071.

44.

R.

K.

Asthana
,
, A.

Srivastava, A.

P.

Singh, Deepali, S.

P.

Singh, G.l

Nath,
R.

Srivastava,

B.

S.

Srivastava.
2006
. Identification of an antimicrobial entity from the cyanobacterium
Fischerella

sp. iso
lated from
bark of
Azadirachta indica

(Neem) tree .
J. Applied Phycology

18 (1), 33.

45.

P. Akhtar, S. Srivastava, A. Srivastava, M. Srivastava,


B. S. Srivastava,
R. Srivastava
2006
.


Rv3303c of
Mycobacterium tuberculosis

protects tubercle bacilli against oxidative stress
in vivo

and


contributes to
virulence in mice.
Microbes and infection

8, 2855.

46.

V. Srivastava, C. Rouanet,
R. Srivastava
, B. Ramalingam, C. Locht, B.S. Srivastava.
2007.

Macrophage
specific
M. tuberculosi
s

genes identified by green fluorescent protein and kanamycin resistance
selection.
Microbiology

153 (Pt 3) 659.

47.

M. Saquib, M. K. Gupta, R. Sagar, Y. S. Prabhakar

, A.


K. Shaw,

R. Kumar, P. R. Maulik, A. Gaikwad, S.
Sinha, A. K. Srivastava, V. Chaturved
i, R. Srivastava, B.S. Srivastava.
2007.

C
-
3 Alkyl/Arylalkyl
-
2,3
-
dideoxy hex
-
2
-
enopyranosides as anti
-

tubercular agents: Synthesis, Biological Evaluation and QSAR
study
.

J. Med. Chem
.,
50
, 2942.

48.


V. Srivastava,
A. Jain, B.S. Srivastava, R. Srivastava.
2008
.

Selection of genes of
Mycobacterium
tuberculosis

upregulated during residen
ce in lungs of infected mice.
Tuberculosis (Edinb).

88 (3) 171.

49.

A. Saxena, V. Srivasrtava, R. Srivastava, B.S. Srivastava
. 2008
.
Identification of genes of
Mycobacterium
tuberculosis

upregulated during anaerobic persistence by fluorescence and kanamycin

resistance
selection.
Tuberculosis (Edinb)
, 88 (6) 518.

50.

R.P.S. Parti, R. Shrivastava, S. Srivastava, A.R. Subramanian, R. Roy, B.S. Srivastava, R. Srivastava.
2008
. .
A transposon insertion mutant of
Mycobacterium fortuitum

attenuated in virulence and
persistence in a murine infection model that is complemented by Rv3291c of Mycobacteri
um
tuberculosis.

Microb
ial

Pathog
enesis
. 45(5
-
6), 370.

51.

A. Gupta, S. Bhakta, S. Kundu, M. Gupta, B.S. Srivastava, R. Srivastava.
2009.

Fast
-
growing, non
-
infectious and intracellularly surviving drug
-
resistant
Mycobacterium aurum
: a model for high
-
throughput antituberculosis drug screening.
J. Antimicrob. Chemotherapy

64(4), 774.

52.

J. Kundu, R. Mazumdar, R. Srivastava, B.S. Srivastava.
2009
.
Intranasal immunization with
recombinant toxin
-
coregulated pilus and cholera toxin B subu
nit protects rabbits against
Vibrio
cholerae

01 challenge.
Fems Immunol

Med Microbiol
. 56(2), 179.

53.

R.K.
Asthana
, A.
Deepal
i, M.K.
Tripathi
, A.
Srivastava
, A.P.
Singh
, S.P.
Singh
, G.
Nath
, R.
Srivastava
, B.S.
Srivastava.
2009
.
Isolation and identification of a new antibacterial entity from the Antarctic
cyanobacterium Nostoc CCC 537.

Journal of Applied Phycology

21(1
), 81.

54.

V. R. Reddy, P. Venkat Reddy, N. N. Mishra, P.K. Shukla, G. Yadav, R. Srivastava, A. K. Shaw.
2010.

Synthesis and biological evaluation of glycal
-
derived novel tetrahydrofuran 1,2,3
-
triazo
les by 'click'
chemistry.

Carbohydr Res
. 345(11), 1515.

55.

R. K. Gupta, B.S. Srivastava, R. Srivastava.
2010.

Comparative expression analysis of rpf
-
like genes of
Mycobacterium tuberculosis

H37Rv under different physiological stress and growth conditions.

Microbiology,

156

, 2714.

56.

Haldar S, Bose M, Chakrabarti P, Daginawala HF, Harinath BC, Kashyap RS, Kulkarni S, Majumdar A,
Prasad HK, Rodrigues C, Srivastava R, Taori GM, Varma
-
Basil M, Tya
gi JS.
.
2011
.
Improved laboratory
diagnosis of tuberculosis
-

The Indian experience.
Tuberculosis (Edinb
).
July
l 15. PMID: 21764383

57.

Singh VK, Srivastava V, Singh V, Rastogi N, Roy R, Shaw AK, Dwiv
edi AK, Srivastava R, Srivastava BS.
2011
.
Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine
to protect against Mycobacterium tuberculosis infection in mic
e.
Vaccine
.
2011
;29(29
-
30):4754
-
60.

58.

Saquib M, Husain I, Sharma S, Yadav G, Singh VK, Sharma SK, Shah P, Siddiqi MI, Kumar B, Lal J, Jain
GK, Srivastava BS, Srivastava R, Shaw AK.
2011
.
2,3
-
dideoxy

hex
-
2
-
enopyranosid
-
4
-
uloses as promising
new anti
-
tubercular agents: design, synthesis, biological evaluation and SAR studies.
Eur J Med Chem.
2011

46(6):2217
-
23.

59.

Singh V, Chandra D, Srivastava BS, Srivastava R

2011
.
Biochemical and transcription analysis of
acetohydroxyacid synthase isoforms in Mycobacterium tuberculosis identifies these enzymes as
potential targets for drug development.
Microbiology.
;157(Pt 1)
:29
-
37.

60.

Singh V, Chandra D, Srivastava BS, Srivastava R

2011
.
Downregulation of Rv0189c, encoding a
dihydroxyacid dehydratase, affects growth of Mycobacterium tuberculosis in vitro and in mice.

Microbiology.
;157(Pt 1):38
-
46.

61.

Sharma SK, Moe TS, Srivastava R, Chandra D, Srivastava BS.
2011.

Functional characterization of
VC1929 of Vibrio cholerae El Tor: role in mannose
-
sensitive hae
magglutination, virulence and
utilization of sialic acid.

Microbiology
.;157(Pt 11):3180
-
6.

62.

Roy KK, Singh S, Sharma SK, Srivastava R, Chaturvedi V, Saxena AK.
2011
.
Synthesis and biological
evaluation of substituted 4
-
arylthiazol
-
2
-
amino derivatives as potent growth inhibitors of replicating
Mycobacterium tuberculosis H₃₇Rv.

Bioorg Med Chem Lett
.;21(18):5589
-
93.

63.

Kashyap VK, Gupta RK, Shrivastava R, Srivastava BS, Srivastava R, Parai

MK, Singh P, Bera S, Panda G.
2012.


In vivo activity of thiophene
-
containing trisubstituted methanes against acute and persistent
infection of non
-
tubercular Mycobacterium fortuitum in a murine
infection model.

J Antimicrob
Chemother
.

;67(5):1188
-
97
.



Patents Granted


1. Mycobacterium tuberculosis

specific


DNA


International
fragment.
Ranjana S
rivastava,

Deepak
Kumar, B.S. Srivastava.


US Patent no. 6,242,585 B1, 5. 6. 2001.


2.
Mycobacterium tuberculosis

specific


DNA


fragment.
Ranjana Srivastava,

Deepak Kumar, B.S.
Srivastava.


US Patent no. 6114514, 05. 09. 2000


3. Mycobacterium tuberculosis

specific


DNA


fragment.
Ranjana Srivastava,
Deepak Kumar, B.S.
Srivastava.


European Patent EP0945462.;
Germany, England, France and Netherland.
08/02/2006


4. Antitubercular extracts of
Salicornia brachiata.
M. R. Rathod
,
B. D. Shethia
,
J. B. Pandya
,
P. K. Ghosh
,
P.J. Dodia
,
Brahm S.
Srivastava
,
Ranjana Srivastava
,
A. Srivastava
,
V. Chaturvedi
,
M. Vairamani
.


U S patent 20070020351, 25.01. 2007.


5. Herbal extracts of
Salicornia

species, process of preparation thereof, use thereof against
tuberculosis preparation thereof, use thereof against tuberculosis.
M. R. Rathod
,
B. D. Shethia
, J.
B.Pandya,
P. K. Ghosh
,
P. J. Dodia
,
Brahm S. Srivastava
,
Ranjana Srivastav
a
,
A. Srivastava
,
V.
Chaturvedi



US Patent 20070248704,
.
25. 10. 2007.


National Patents Granted


1.

A process for the production of bifunctional glucose and cellobiose inhibition resistant cellulase from
a new microorganism
Bacillus subtilis
.
R. Srivastava

and B.S. Srivastava.


Patent no 187232; 29.9.2002

2.

A process for the

production of bifunctional cellulase from
Escherichia coli
.
R. Srivastava
, K.K.
Srivastava and B.S. Srivastava.


Patent no. 187959; 3.7.
2003.

3.

A process for the preparation of novel combinatorial library of 3
-
substituted amino
-
3
-
glycosylated
propanoates useful as antifungal and antibacterial agents . R.P. Tripathi, B. Kundu, P. K. Shukla, S.
Sinha,
Ranjana Srivastava
, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava.


Patent no. 194984; 17.03.2006

4.

A novel combina
torial library of 3
-
substituted amino
-
3
-
glycosylated propanamides useful as
antifungal and antibacterial agents. R. P. Tripathi, P. K. Shukla, S. Sinha,
Ranjana Srivastava
, A.
Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava.


Pa
tent no. 196956; 23.06.2006.

5.

A process for the preparation of novel combinatorial library of N1
-
glycosylated and N3
-

substituted
ureas and thioureas useful as antitubercular agents . R. P. Tripathi, V. K. Tiwari, R. C. Mishra,
Ranjana
Srivastava
, S. Sinha
, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava.

Patent no. 199556; 16.10.2006.

6.

A process for the preparation of novel N
1
, N
n

di glycosylated diaminoalcohol useful in chemotherapy
of tubercular infections. R. P. Tripathi, V.
K. Tiwari, N. Tewari,
Ranjana Srivastava
, A. Srivastava, V.
Chaturvedi, K.K. Srivastava, S. Sinha, B. S. Srivastava,

Patent no. 199829; 28.9.2007.


National Patents Filed


1.

A process for the preparation of 1,3,5
-
thiazidin
--
2
-
thiones useful in chemotherapy of tubercular
infections. R. P. Tripathi, D. Katiyar,
Ranjana Srivastava
, A. Srivastava, V. Chaturvedi, K. K. Srivastava,
Brahm Shanker Srivastava.


1098 DEL 2004; 6.11.2004.

2. Novel 1,3,5
-
thiazidine
-
2
-
thiones useful in chemotherapy of tubercular infections. R. P. Tripathi, D.
Katiyar,
Ranjana Srivastava
, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shankar Srivastava


1100 DEL 2004; 6.11.2004.

3. A process for the synthesis
of Novel Phenyl Cyclopropyl methanones useful as antitubercular agents. R.
Grover, R.C. Mishra, S.S. Verma, R.P. Tripathi, Raja Roy, A.K. Dwivedi, S. Singh,
R. Srivastava
, A.
Srivastava, V. Chaturvedi, Manju Y. Krishnan, B. S. Srivastava.


0636 DEL/
2004; 31.3.2004 .

4. Herbal extracts of Salicornia species, process of preparation thereof, use thereof against tuberculosis.
M.R. Rathod, B.S. Shetheia, J.B. Pandeya, P.K. Ghosh, P.J. Dodia, B.S. Srivastava,
R. Srivastava
, A.
Srivastava, V. Chaturvedi. N

034/ NF/2003

4.

Two assays to determine the activity of Isocitrate lyase from
Mycobacterium tuberculosis
and other
mycobacteria . Manish Gupta,
Ranjana Srivastava
, Brahm S. Srivastava INF/PAT/09/2004

5.

Mycobacterium tuberculosis

specific DNA probes and a set of oligonucleotide primers for rapid
diagnosis and to identify clinical isolates

.
Ranjana Srivastava
,

Deepak Kumar and Brahm S.
Srivastava.

1760/DEL/04, 15.9.05

6.

A Process for the preparation of novel 4
-
Nitrobutanoate Inhibitors of Isocitrate Lyase from
Mycobacterium tuberculosis
.
Ranjana Srivastava
, Brahm S. Srivastava M. K. Gupta, R. P. Tripathi, N.
Tiwari, D. Katiyar, R. Ravishankar .

0671/DEL/2006; 07.12.2006.

7.

C
-
3 aryl and alkyl substituted 2,3
-
dideoxyglucopyranoside as potential antitubercular agent. Ram
sagar, M. Saquib, A.K. Shaw, A.N. Gaikwad, S.K. Sinha, A. Srivastava, V. Chaturvedi, M.Y. Krishnan,
Ranjana Srivastava
, B.S. Srivastava.

0533 DEL/2006; 23.02
.2006



Sequences submitted in EMBL database


Two
Mycobacterium fortuitum

insertion sequences IS
21
9 and IS
220
. Sequence submitted to EMBL


Accession AJ 315500. 2002. These are new IS elements.



Technology Transferred


A new diagnostic reagent based on sequence specific
M
.
tuberculosis

DNA fragment: has been deveopled,
licensed and commercialized as
MycoView MTB PCR Detection Kit

by Biotron Healthcare (I) Pvt. Ltd. India
for early diagnosis of tuberculosis. The probe is

a 1291 bp genomic DNA patented in USA, Europe and
India.